Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea
· Delayed Price · Currency is KRW 1,579,000
-65,000 (-3.95%)
At close: Mar 9, 2026
Samsung Biologics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 4,556,972 | 3,497,146 | 3,694,589 | 3,001,295 | 1,568,007 | Upgrade
|
| Other Revenue | -0 | -0 | - | -0 | - | Upgrade
|
| Revenue | 4,556,972 | 3,497,146 | 3,694,589 | 3,001,295 | 1,568,007 | Upgrade
|
| Revenue Growth (YoY) | 30.30% | -5.34% | 23.10% | 91.41% | 34.62% | Upgrade
|
| Cost of Revenue | 2,056,131 | 1,798,093 | 1,900,080 | 1,540,526 | 844,657 | Upgrade
|
| Gross Profit | 2,500,841 | 1,699,053 | 1,794,509 | 1,460,769 | 723,350 | Upgrade
|
| Selling, General & Admin | 357,259 | 313,046 | 535,421 | 380,456 | 169,630 | Upgrade
|
| Research & Development | 37,181 | 36,711 | 81,588 | 45,884 | 954.22 | Upgrade
|
| Amortization of Goodwill & Intangibles | 13,797 | 10,948 | 9,977 | 7,700 | 4,572 | Upgrade
|
| Other Operating Expenses | 5,970 | 4,688 | 10,339 | 7,448 | 1,804 | Upgrade
|
| Operating Expenses | 431,620 | 377,686 | 680,829 | 477,142 | 186,040 | Upgrade
|
| Operating Income | 2,069,221 | 1,321,366 | 1,113,680 | 983,627 | 537,309 | Upgrade
|
| Interest Expense | -29,171 | -34,123 | -81,596 | -64,064 | -14,707 | Upgrade
|
| Interest & Investment Income | 46,034 | 54,404 | 95,650 | 53,293 | 9,656 | Upgrade
|
| Earnings From Equity Investments | 43,085 | 2,659 | -499.42 | 27,260 | 13,853 | Upgrade
|
| Currency Exchange Gain (Loss) | -7,447 | 41,832 | -11,186 | -63,503 | 17,874 | Upgrade
|
| Other Non Operating Income (Expenses) | 2,352 | 1,361 | 2,652 | 2,347 | 4,494 | Upgrade
|
| EBT Excluding Unusual Items | 2,124,074 | 1,387,500 | 1,118,701 | 938,960 | 568,479 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 5,152 | 72,653 | 269.12 | Upgrade
|
| Gain (Loss) on Sale of Assets | -5,443 | -1,949 | -3,866 | -2,588 | -7,466 | Upgrade
|
| Asset Writedown | - | -682.1 | - | - | - | Upgrade
|
| Pretax Income | 2,118,631 | 1,384,869 | 1,119,987 | 1,009,025 | 561,283 | Upgrade
|
| Income Tax Expense | 504,301 | 344,567 | 262,296 | 210,968 | 167,693 | Upgrade
|
| Earnings From Continuing Operations | 1,614,330 | 1,040,302 | 857,691 | 798,056 | 393,589 | Upgrade
|
| Earnings From Discontinued Operations | 170,022 | 43,014 | - | - | - | Upgrade
|
| Net Income to Company | 1,784,352 | 1,083,316 | 857,691 | 798,056 | 393,589 | Upgrade
|
| Net Income | 1,784,352 | 1,083,316 | 857,691 | 798,056 | 393,589 | Upgrade
|
| Net Income to Common | 1,784,352 | 1,083,316 | 857,691 | 798,056 | 393,589 | Upgrade
|
| Net Income Growth | 64.71% | 26.31% | 7.47% | 102.76% | 63.33% | Upgrade
|
| Shares Outstanding (Basic) | 67 | 71 | 46 | 45 | 43 | Upgrade
|
| Shares Outstanding (Diluted) | 67 | 71 | 46 | 45 | 43 | Upgrade
|
| Shares Change (YoY) | -5.85% | 53.75% | 1.95% | 5.51% | - | Upgrade
|
| EPS (Basic) | 26628.00 | 15221.00 | 18528.27 | 17592.79 | 9146.19 | Upgrade
|
| EPS (Diluted) | 26628.00 | 15221.00 | 18528.27 | 17577.11 | 9146.19 | Upgrade
|
| EPS Growth | 74.94% | -17.85% | 5.41% | 92.18% | 63.33% | Upgrade
|
| Free Cash Flow | 856,067 | 355,682 | 671,158 | -3,792 | 48,343 | Upgrade
|
| Free Cash Flow Per Share | 12775.14 | 4997.47 | 14498.68 | -83.52 | 1123.38 | Upgrade
|
| Gross Margin | 54.88% | 48.58% | 48.57% | 48.67% | 46.13% | Upgrade
|
| Operating Margin | 45.41% | 37.78% | 30.14% | 32.77% | 34.27% | Upgrade
|
| Profit Margin | 39.16% | 30.98% | 23.21% | 26.59% | 25.10% | Upgrade
|
| Free Cash Flow Margin | 18.79% | 10.17% | 18.17% | -0.13% | 3.08% | Upgrade
|
| EBITDA | 2,702,858 | 1,920,468 | 1,603,462 | 1,291,892 | 699,098 | Upgrade
|
| EBITDA Margin | 59.31% | 54.92% | 43.40% | 43.04% | 44.59% | Upgrade
|
| D&A For EBITDA | 633,637 | 599,101 | 489,782 | 308,264 | 161,789 | Upgrade
|
| EBIT | 2,069,221 | 1,321,366 | 1,113,680 | 983,627 | 537,309 | Upgrade
|
| EBIT Margin | 45.41% | 37.78% | 30.14% | 32.77% | 34.27% | Upgrade
|
| Effective Tax Rate | 23.80% | 24.88% | 23.42% | 20.91% | 29.88% | Upgrade
|
| Advertising Expenses | 6,615 | 7,180 | 11,916 | 8,829 | 5,349 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.